A Case of Metastatic Fumarate Hydratase-Deficient–like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab

Takanori Sekito; Atsushi Takamoto; Yasuyuki Kobayashi; Masao Mitsui; Shogo Watari; Risa Kubota; Takuya Sadahira; Takehiro Iwata; Shingo Nishimura; Kohei Edamura; Motoo Araki; Masami Watanabe; Toyohiko Watanabe; Rei Shibata; Daisuke Ennishi; Yasutomo Nasu

A Case of Metastatic Fumarate Hydratase-Deficient–like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab

Takanori Sekito, Atsushi Takamoto, Yasuyuki Kobayashi, Masao Mitsui, Shogo Watari, Risa Kubota, Takuya Sadahira, Takehiro Iwata, Shingo Nishimura, Kohei Edamura, Motoo Araki, Masami Watanabe, Toyohiko Watanabe, Rei Shibata, Daisuke Ennishi, Yasutomo Nasu

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

We report a 62-year-old male with metastatic fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) without fumarate hydratase (FH) mutation (FH-deficient–like RCC). The International Metastatic RCC Database Consortium risk score was intermediate, and immunotherapy with nivolumab and ipilimumab (Ipi/Nivo) was initiated. Four cycles of Ipi/Nivo and 5 cycles of nivolumab resulted in a complete response of the metastases. Hypophysitis occurred as an immune-related adverse event after four cycles of Ipi/Nivo. The prognosis of patients with FH-deficient RCC is generally poor. Few reports of FH-deficient RCC successfully treated with Ipi/Nivo have been published. Ipi/Nivo can be effective for treating FH-deficient RCC.

Original language	English
Pages (from-to)	397-402
Number of pages	6
Journal	Acta medica Okayama
Volume	75
Issue number	3
Publication status	Published - 2021

Keywords

fumarate hydratase
fumarate hydratase-deficient renal cell carcinoma
ipilimumab
nivolumab
renal cell carcinoma

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Cite this

Sekito, T., Takamoto, A., Kobayashi, Y., Mitsui, M., Watari, S., Kubota, R., Sadahira, T., Iwata, T., Nishimura, S., Edamura, K., Araki, M., Watanabe, M., Watanabe, T., Shibata, R., Ennishi, D., & Nasu, Y. (2021). A Case of Metastatic Fumarate Hydratase-Deficient–like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab. Acta medica Okayama, 75(3), 397-402.

Sekito, T, Takamoto, A, Kobayashi, Y, Mitsui, M, Watari, S, Kubota, R, Sadahira, T , Iwata, T , Nishimura, S , Edamura, K , Araki, M , Watanabe, M , Watanabe, T, Shibata, R, Ennishi, D & Nasu, Y 2021, 'A Case of Metastatic Fumarate Hydratase-Deficient–like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab', Acta medica Okayama, vol. 75, no. 3, pp. 397-402.

@article{ff160b5894e4410aa53aff470543c2a7,

title = "A Case of Metastatic Fumarate Hydratase-Deficient–like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab",

abstract = "We report a 62-year-old male with metastatic fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) without fumarate hydratase (FH) mutation (FH-deficient–like RCC). The International Metastatic RCC Database Consortium risk score was intermediate, and immunotherapy with nivolumab and ipilimumab (Ipi/Nivo) was initiated. Four cycles of Ipi/Nivo and 5 cycles of nivolumab resulted in a complete response of the metastases. Hypophysitis occurred as an immune-related adverse event after four cycles of Ipi/Nivo. The prognosis of patients with FH-deficient RCC is generally poor. Few reports of FH-deficient RCC successfully treated with Ipi/Nivo have been published. Ipi/Nivo can be effective for treating FH-deficient RCC.",

keywords = "fumarate hydratase, fumarate hydratase-deficient renal cell carcinoma, ipilimumab, nivolumab, renal cell carcinoma",

author = "Takanori Sekito and Atsushi Takamoto and Yasuyuki Kobayashi and Masao Mitsui and Shogo Watari and Risa Kubota and Takuya Sadahira and Takehiro Iwata and Shingo Nishimura and Kohei Edamura and Motoo Araki and Masami Watanabe and Toyohiko Watanabe and Rei Shibata and Daisuke Ennishi and Yasutomo Nasu",

note = "Publisher Copyright: {\textcopyright} 2021 by Okayama University Medical School.",

year = "2021",

language = "English",

volume = "75",

pages = "397--402",

journal = "Acta Medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "3",

}

TY - JOUR

T1 - A Case of Metastatic Fumarate Hydratase-Deficient–like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab

AU - Sekito, Takanori

AU - Takamoto, Atsushi

AU - Kobayashi, Yasuyuki

AU - Mitsui, Masao

AU - Watari, Shogo

AU - Kubota, Risa

AU - Sadahira, Takuya

AU - Iwata, Takehiro

AU - Nishimura, Shingo

AU - Edamura, Kohei

AU - Araki, Motoo

AU - Watanabe, Masami

AU - Watanabe, Toyohiko

AU - Shibata, Rei

AU - Ennishi, Daisuke

AU - Nasu, Yasutomo

PY - 2021

Y1 - 2021

N2 - We report a 62-year-old male with metastatic fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) without fumarate hydratase (FH) mutation (FH-deficient–like RCC). The International Metastatic RCC Database Consortium risk score was intermediate, and immunotherapy with nivolumab and ipilimumab (Ipi/Nivo) was initiated. Four cycles of Ipi/Nivo and 5 cycles of nivolumab resulted in a complete response of the metastases. Hypophysitis occurred as an immune-related adverse event after four cycles of Ipi/Nivo. The prognosis of patients with FH-deficient RCC is generally poor. Few reports of FH-deficient RCC successfully treated with Ipi/Nivo have been published. Ipi/Nivo can be effective for treating FH-deficient RCC.

AB - We report a 62-year-old male with metastatic fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) without fumarate hydratase (FH) mutation (FH-deficient–like RCC). The International Metastatic RCC Database Consortium risk score was intermediate, and immunotherapy with nivolumab and ipilimumab (Ipi/Nivo) was initiated. Four cycles of Ipi/Nivo and 5 cycles of nivolumab resulted in a complete response of the metastases. Hypophysitis occurred as an immune-related adverse event after four cycles of Ipi/Nivo. The prognosis of patients with FH-deficient RCC is generally poor. Few reports of FH-deficient RCC successfully treated with Ipi/Nivo have been published. Ipi/Nivo can be effective for treating FH-deficient RCC.

KW - fumarate hydratase

KW - fumarate hydratase-deficient renal cell carcinoma

KW - ipilimumab

KW - nivolumab

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85109448704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85109448704&partnerID=8YFLogxK

M3 - Article

C2 - 34176946

AN - SCOPUS:85109448704

SN - 0386-300X

VL - 75

SP - 397

EP - 402

JO - Acta Medica Okayama

JF - Acta Medica Okayama

IS - 3

ER -

A Case of Metastatic Fumarate Hydratase-Deficient–like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this